The agreement, disclosed in the drugmaker’s latest annual report, ends a probe opened three years ago by the U.S. attorney in Boston. Novartis is accused of donating money to independent foundations that help Medicare beneficiaries pay their out-of-pocket costs for its Gleevec cancer medication and Gilenya multiple sclerosis treatment.
A Novartis spokesman told STAT the payment agreement was a “mutually acceptable resolution” and that “independent copay foundations are legitimate charitable foundations that help patients cover out-of-pockets costs associated with their care.”
Federal prosecutors are more aggressively pursuing drugmakers for donating to programs that provide patients with free medication or copay assistance. Most recently, Alexion Pharmaceuticals disclosed it paid $13 million to resolve claims concerning payments to patient organizations.
Read the full report here.
More articles on pharmacy:
Viewpoint: It’s time for pharma to have its ‘tobacco moment’
Top 10 fatal or harmful prescribing errors
‘Wacky’ rebate system to blame for high patient drug prices, FDA chief says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.